TransCode Therapeutics has initiated a formal strategic process to evaluate alternatives for maximizing the value of its oncology portfolio, including its lead Phase 2a candidate TTX-MC138. The company has engaged Tungsten Advisors to explore potential licensing deals, development partnerships, asset sales, or business combinations.
Transcode Therapeutics $841K Debt Financing with YA II PN, Ltd.
TransCode Therapeutics made a $840,975 prepayment to Yorkville to resolve a potential 'Amortization Event' triggered by its stock price falling below a $1.72 floor price. In exchange for the payment, which includes $759,000 in principal plus premiums and interest, Yorkville waived the amortization requirement through October 31, 2026. Approximately $4.1 million in principal remains outstanding under the convertible notes.
TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities reported, and three patients remained progression-free at the one-year mark. The company believes the durability of disease control warrants continued clinical evaluation of the RNA-based therapeutic candidate.
Thomas A. Fitzgerald resigned as CFO and Director of TransCode Therapeutics effective September 9, 2026. The company entered into a separation agreement providing for up to $1.25 million in severance payments, accelerated vesting of existing equity, and a new grant of 185,000 stock options. A portion of the cash severance and option vesting is contingent on the company achieving specific funding thresholds of $5 million and $10 million.